ReviewMolecules (Basel, Switzerland)2010
Mu-conotoxins as leads in the development of new analgesics.
Review in Molecules (Basel, Switzerland), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 49 citations in OpenAlex.
- A novel proline-rich M-superfamily conotoxin that can simultaneously affect sodium, potassium and calcium currents.The journal of venomous animals and toxins including tropical diseases · 2021Article
- Structural and Functional Analyses of Cone Snail Toxins.Marine drugs · 2019Review
- In Silico Analysis of the Subtype Selective Blockage of KCNA Ion Channels through the µ-Conotoxins PIIIA, SIIIA, and GIIIA.Marine drugs · 2019Article
- Role of the disulfide bond on the structure and activity of μ-conotoxin PIIIA in the inhibition of NaRSC advances · 2019Article
- µ-Conotoxins Modulating Sodium Currents in Pain Perception and Transmission: A Therapeutic Potential.Marine drugs · 2017Review
- The Role of Individual Disulfide Bonds of μ-Conotoxin GIIIA in the Inhibition of NaMarine drugs · 2016Article
- Review
- Article
- Conotoxin gene superfamilies.Marine drugs · 2014Review
- Structure and function of μ-conotoxins, peptide-based sodium channel blockers with analgesic activity.Future medicinal chemistry · 2014Review
- Computational approaches for designing potent and selective analogs of peptide toxins as novel therapeutics.Future medicinal chemistry · 2014Review
- Interactions of disulfide-deficient selenocysteine analogs of μ-conotoxin BuIIIB with the α-subunit of the voltage-gated sodium channel subtype 1.3.The FEBS journal · 2014Article
- Molecular dynamics study of binding of µ-conotoxin GIIIA to the voltage-gated sodium channel Na(v)1.4.PloS one · 2014Article
- Article
- The insecticidal potential of venom peptides.Cellular and molecular life sciences : CMLS · 2013Review
- Designing a C84 fullerene as a specific voltage-gated sodium channel blocker.Nanoscale research letters · 2013Article
- Strategies for the development of conotoxins as new therapeutic leads.Marine drugs · 2013Review
- Computational studies of marine toxins targeting ion channels.Marine drugs · 2013Review
- Mammalian neuronal sodium channel blocker μ-conotoxin BuIIIB has a structured N-terminus that influences potency.ACS chemical biology · 2013Article
- Distinct disulfide isomers of μ-conotoxins KIIIA and KIIIB block voltage-gated sodium channels.Biochemistry · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Voltage-gated sodium channels (VGSCs) contain a specific binding site for a family of cone shell toxins known as mu-conotoxins. As some VGSCs are involved in pain perception and mu-conotoxins are able to block these channels, mu-conotoxins show considerable potential as analgesics. Recent studies have advanced our understanding of the three-dimensional structures and structure-function relationships of the mu-conotoxins, including their interaction with VGSCs. Truncated peptide analogues of the native toxins have been created in which secondary structure elements are stabilized by non-native linkers such as lactam bridges. Ultimately, it would be desirable to capture the favourable analgesic properties of the native toxins, in particular their potency and channel sub-type selectivity, in non-peptide mimetics. Such mimetics would constitute lead compounds in the development of new therapeutics for the treatment of pain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.